Catalyst Wire Dossier Catalyst Wire Dossier

SHR4640

· Jiangsu HengRui Medicine Co., Ltd.
Drug timelines are a Plus or Pro feature.

11 regulatory and trial events tracked for SHR4640, covering 2017-02-28 to 2026-04-07. Get the full timeline:

Most recent: Clinical Trial Update: The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia [Phase 2]

See pricing